Transmedics Group Inc [TMDX] stock is trading at $67.55, up 0.90%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The TMDX shares have gain 11.07% over the last week, with a monthly amount glided 13.95%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Transmedics Group Inc [NASDAQ: TMDX] stock has seen the most recent analyst activity on December 17, 2024, when JP Morgan downgraded its rating to a Neutral and also revised its price target to $75 from $116. Previously, Needham downgraded its rating to Hold on November 22, 2024. On October 29, 2024, Oppenheimer reiterated its Outperform rating and revised its price target to $125 on the stock. Needham reiterated its Buy rating and decreased its price target to $109 on October 29, 2024. Robert W. Baird initiated its recommendation with a Outperform and recommended $200 as its price target on September 24, 2024. Needham started tracking with a Buy rating for this stock on August 21, 2024, and assigned it a price target of $208. In a note dated June 06, 2024, Cantor Fitzgerald initiated an Overweight rating and provided a target price of $161 on this stock.
Transmedics Group Inc [TMDX] stock has fluctuated between $55.00 and $177.37 over the past year. Currently, Wall Street analysts expect the stock to reach $110.6 within the next 12 months. Transmedics Group Inc [NASDAQ: TMDX] shares were valued at $67.55 at the most recent close of the market. An investor can expect a potential return of 63.73% based on the average TMDX price forecast.
Analyzing the TMDX fundamentals
Transmedics Group Inc [NASDAQ:TMDX] reported sales of 401.09M for the trailing twelve months, which represents a growth of 63.72%. Gross Profit Margin for this corporation currently stands at 0.59% with Operating Profit Margin at 0.08%, Pretax Profit Margin comes in at 0.08%, and Net Profit Margin reading is 0.08%. To continue investigating profitability, this company’s Return on Assets is posted at 0.04, Equity is 0.19 and Total Capital is 0.04. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of2.47.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 66.47 points at the first support level, and at 65.38 for the second support level. However, for the 1st resistance point, the stock is sitting at 69.07, and for the 2nd resistance point, it is at 70.58.
Ratios To Look Out For
For context, Transmedics Group Inc’s Current Ratio is 8.20. Further, the Quick Ratio stands at 7.33, while the Cash Ratio is 5.5. Considering the valuation of this stock, the price to sales ratio is 5.65, the price to book ratio is 10.80 and price to earnings (TTM) ratio is 72.37.
Transactions by insiders
Recent insider trading involved Khayal Tamer I, Chief Commercial Officer, that happened on Jan 07 ’25 when 1083.0 shares were sold. Chief Commercial Officer, Khayal Tamer I completed a deal on Dec 02 ’24 to sell 1084.0 shares. Meanwhile, Chief Commercial Officer Khayal Tamer I sold 1458.0 shares on Nov 11 ’24.
